bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.10.14.758961

Elevated polyadenylated histone gene transcription in human cancer

Paranal, R. M.·Bryson, T. D.·Rios Rios, G. N.·Nguyen, K. K.·Ahmad, K.·Henikoff, S.
View original source ↗Export metadata ↓

Abstract

Histone production is tightly restricted to S-phase to prevent genomic instability, yet human cancers with an overabundance of RNA Polymerase II (RNAPII) at histone genes are associated with aggressive cancers. To better understand histone gene overexpression in cancer, we applied a quantitative PCR assay to measure total replication-coupled histone output across the histone gene clusters using cell line models. We observed pervasive accumulation of polyadenylated histone transcripts, supported by analysis of >1,400 RNA-sequencing datasets in human cancers, with more than 70% of patients showing tumor specific increases. This alternative processing preferentially enriches for histone H2B, which lacks replication independent variants, across >8,300 tumors comprising diverse cancer types and transcriptional subtypes. We also found that disruption of nuclear components required to maintain RNAPII levels at the histone genes increased polyadenylated histone transcripts. Our results suggest that S-phase-dependent histone genes are subject to unscheduled gap phase transcription in human cancer.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Paranal, R. M., Bryson, T. D., Rios Rios, G. N., Nguyen, K. K., Ahmad, K., Henikoff, S.. 2026-10-20. Elevated polyadenylated histone gene transcription in human cancer. https://doi.org/10.64898/2026.10.14.758961

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Developmental origins of thymic B-cell lymphomas

The thymus provides a specialized niche for lymphocyte differentiation, yet the developmental trajectories of its rare B-cell population and their relationship to thymic B-cell lymphomagenesis remain poorly understood. Here, we integrate single-cell multiomics and spatial profiling across human tissues to delineate a B-cell differentiation program selectively represented in the human thymus. This program links CCL17 and germinal center-like B-cell states along a trajectory distinct from canonical germinal center differentiation and can be recapitulated in vitro by signals operating in the thymic medulla. Extending this framework across human B-cell lymphomas, we identify an inherent malignant cell state in PMBCL that shares transcriptional and epigenetic features with CCL17 thymic B cells. This malignant state associates with early clonal positions in reconstructed B-cell receptor phylogenies and persists within tumor microenvironments distinct from the thymic niche. Together, these findings support a model in which thymus-specific B-cell differentiation programs are redeployed during thymic B-cell lymphomagenesis.

cancer biology↗
bioRxiv2026

Live immunogenic melanoma cells generated by etoposide treatment upregulate B2M and lose tumor-forming potential

Cytotoxic chemotherapy has been the primary cancer treatment modality for decades, however, chemotherapy drugs do not selectively target cancer cells. These drugs are toxic to all proliferating cells including immune cells that constitute the host-defense system against pathogens and cancer cells. In an effort to develop non-toxic combinations of chemotherapy and immunotherapies for cancer, we previously reported in Sriram et al. 2021 that etoposide-treated B16 melanoma cells expressing ovalbumin, when co-cultured in vitro with dendritic cells and T-cells, enhance T-cell activation. The live fraction of melanoma cells after etoposide treatment was critical to promote T-cell activation as dead cells alone or in combination with cell-free supernatants were not effective. In this study, we show that the live fraction of etoposide-treated B16-Ova cells, which gain the ability to stimulate T-cells, are growth-arrested, but remain viable past the co-incubation period with dendritic cells and T-cells post etoposide washout. Furthermore, using a soft-agar colony-formation assay as a proxy for tumor-forming potential, we show that these live etoposide-treated B16-Ova cells have drastically reduced ability to form colonies displaying a near-complete loss of anchorage-independent growth. We also show that etoposide treatment upregulates the production of Beta-2-microglobulin (B2M), a subunit of Class I MHC. Intriguingly, we observed using immunofluorescence that the live etoposide-treated B16-Ova cells show enhanced intracellular perinuclear B2M accumulation but B2M surface staining, while detectable, is not enhanced by etoposide treatment. Furthermore, while the live etoposide-treated B16-Ova cells express Class I MHC protein, there is only a marginal drug treatment-induced increase observed in the expression levels by western blotting. Our results suggest that T-cell activation by live etoposide-treated B16-Ova cells is likely not driven by drug treatment-induced enhancement in cell surface levels of Class I MHC and point to other mechanisms.

cancer biology↗
bioRxiv2026

GLP1R agonists and vorasidenib converge on peroxynitrite-mediated cytotoxicity in mutant IDH glioma

Mutations in isocitrate dehydrogenase 1 or 2 (mIDH) generate the oncometabolite D-2-hydroxyglutarate that drives tumorigenesis in a distinct molecular class of gliomas. The mIDH inhibitor vorasidenib slows tumor growth, but disease progression remains a challenge, identifying a need for strategies that deepen and prolong therapeutic response. Here, we show that glucagon-like peptide-1R (GLP1R) agonists synergize with vorasidenib in patient-derived and murine models of mIDH glioma. Mechanistically, GLP1R agonists activate cAMP-protein kinase A signaling and induce nitric oxide synthase 1-dependent nitric oxide production in mIDH glioma cells. Nitric oxide inhibits aconitase and ribonucleotide reductase via S-nitrosylation, thereby disrupting the tricarboxylic acid cycle, depleting deoxyribonucleotides, blocking DNA synthesis, and exerting a cytostatic inhibition of tumor cell proliferation. Concomitantly, vorasidenib relieves D-2HG-driven suppression of pyruvate dehydrogenase, thereby increasing mitochondrial superoxide production and suppressing proliferation without cytotoxicity. When combined, GLP1R agonist-induced nitric oxide and vorasidenib-induced superoxide converge to generate peroxynitrite, which damages lipids and DNA, and triggers apoptosis in mIDH glioma cells. Combining a GLP1R agonist with vorasidenib recapitulates these metabolic and pharmacodynamic effects in mice bearing intracranial mIDH tumors, induces tumor regression, and significantly prolongs survival relative to each monotherapy in vivo. Collectively, our studies demonstrate that GLP1R agonism and mIDH inhibition induce distinct alterations in mitochondrial redox metabolism that converge to produce synergistic cytotoxicity and provide a mechanistic basis for clinical evaluation of this therapeutic strategy in patients with mIDH glioma.

cancer biology↗